References

zabmedvestnik

Забайкальский медицинский вестник

Transbaikalian Medical Bulletin

1998-6173

Читинская государственная медицинская академия

10.52485/19986173_2022_1_44

zabmedvestnik-124

Research Article

НАУЧНЫЕ ОБЗОРЫ

SCIENTIFIC REVIEWS

ЛИМФОТОКСИН АЛЬФА: БИОЛОГИЧЕСКОЕ И КЛИНИЧЕСКОЕ ЗНАЧЕНИЕ

LYMPHOTOXIN ALPHA: BIOLOGICAL AND CLINICAL SIGNIFICANCE

Гаращенко

Н. E.

Garashchenko

N. E.

664003, г. Иркутск, ул. Красного Восстания, 1

664003, Irkutsk, 1 Krassnogo vosstanija St.

Семинский

И. Ж.

Seminskiy

I. Zh.

664003, г. Иркутск, ул. Красного Восстания, 1

664003, Irkutsk, 1 Krassnogo vosstanija St.

Федеральное государственное бюджетное образовательное учреждение высшего образования «Иркутский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияIrkutsk state medical universityRussian Federation

2022

03082024

014455

2024

Гаращенко Н.E., Семинский И.Ж.

Garashchenko N.E., Seminskiy I.Z.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.zabmedvestnik.ru/jour/article/view/124

Лимфотоксин альфа – один из представителей семейства факторов некроза опухоли. За почти сорок лет исследований было доказано его патофизиологическое значение как одного из цитокинов, принимающих участие в пролиферативных и воспалительных процессах в организме. Изучение генетического профиля позволило доказать взаимосвязь целого ряда однонуклеотидных полиморфизмов гена лимфотоксина с различными нозологическими формами. В клинической практике играет роль в терапии ревматических заболеваний, в первую очередь ревматоидного артрита. Изучается его роль в развитии онкологических патологий. Разрабатываются препараты, воздействующие на систему лимфотоксина. Также продолжаются исследования многообразия его генетической структуры, биохимических особенностей действия в норме и при патологии. Остаются неизученными многие аспекты, касающиеся влияния лимфотоксина на различные процессы. В статье отражены основные сведения, полученные за многолетний период исследований данного цитокина, его гена и системы его рецепторов, а также его роли при патологических состояниях и терапевтических препаратов, влияющих на его функционирование.

Lymphotoxin α is a one of the tumor necrosis factor family ligand. For almost forty years its pathophysiologic importance as proliferative and inflammatory cytokine was validated. Correlation between some single nucleotide polymorphism and nosological entity was clarified with lyphotoxin’s gene investigation. In clinic it uses in the treatment protocols of rheumatic diseases especially rheumatoid arthritis. Its role in the oncopathological processes is being studied. Lymphotoxin’s system influenced medicines are being researched. Moreover the studying of genomic structure and biochemical aspects under normal and pathological conditions is in process. There are many points of lymphotoxin’s influence on various metabolic ways. The main research results of this cytokine, its genetic structure and its receptors role in pathological conditions and therapeutic approaches, influencing on its system, were observed in the article.

лимфотоксин альфасемейство факторов некроза опухолейревматоидный артритонкологические заболеванияоднонуклеотидные полиморфизмы

lymphotoxin alphatumor necrosis factor ligands familyrheumatoid arthritisoncological diseasessingle nucleotide polymorphisms

References1

Aggarwal B.B., Gupta S.C., Kim J.H. (2012). Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood, The Journal of the American Society of Hematology, 119 (3), 651-665.

Aggarwal B.B. (2003). Signalling pathways of the TNF superfamily: a double-edged sword. Nature reviews immunology, 3 (9), 745-756.

Gubernatorova E.O., Polinova A.I., Petropavlovskiy M.M., Namakanova O.A., Medvedovskaya A.D., Zvartsev R.V., Telegin G.B., Drutskaya M.S., Nedospasov S.A. (2021). Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice. Cancers, 13 (8), 1775.

Dostert C., Grusdat M., Letellier E., Brenner D. (2019). The TNF family of ligands and receptors: communication modules in the immune system and beyond. Physiological reviews, 99 (1), 115-160.

Roach D.R., Briscoe H., Saunders B., France M.P., Riminton S., Britton W.J. (2001). Secreted lymphotoxin-α is essential for the control of an intracellular bacterial infection. Journal of Experimental Medicine, 193 (2), 239-246.

Buhrmann C., Popper B., Aggarwal B.B., Shakibaei M. (2017). Resveratrol downregulates inflammatory pathway activated by lymphotoxin α (TNF-β) in articular chondrocytes: Comparison with TNF-α. PLoS One, 12 (11), e0186993.

Yokley B.H., Selby S.T., Posch P.E. (2013). A stimulation-dependent alternate core promoter links lymphotoxin α expression with TGF-β1 and fibroblast growth factor-7 signaling in primary human T cells. The Journal of Immunology, 190 (9), 4573-4584.

Calmon-Hamaty F., Combe B., Hahne M., Morel J. (2011). Lymphotoxin α stimulates proliferation and pro-inflammatory cytokine secretion of rheumatoid arthritis synovial fibroblasts. Cytokine, 53 (2), 207-214.

Piao W., Kasinath V., Saxena V., Lakhan R., Iyyathurai J., Bromberg J. S. (2021). LTβR Signaling Controls Lymphatic Migration of Immune Cells. Cells, 10 (4), 747.

Tumanov A.V., Grivennikov S.I., Shakhov A.N., Rybtsov S.A., Koroleva E.P., Takeda J., Nedospasov S.A., Kuprash D.V. (2003). Dissecting the role of lymphotoxin in lymphoid organs by conditional targeting. Immunological reviews, 195 (1), 106-116.

Guo S., Zuo Q., Li X., He Y., Zhou Y. (2020). Association between the Lymphotoxin-α A252g Gene Polymorphism and the Risk of Sepsis and Mortality: A Meta-Analysis. BioMed research international, 2020.

Шебзухов Ю.В., Купраш Д.В. (2011). РЕГУЛЯЦИЯ ТРАНСКРИПЦИИ ГЕНОВ ЛОКУСА TNF/LT В КЛЕТКАХ ИММУННОЙ СИСТЕМЫ. Молекулярная биология, 45 (1), 56-67.

Shebzukhov Y.V., Kuprash D.V. (2011). Transcriptional regulation of TNF/LT locus in immune cells. Molekulyarnaya biologiya, 45 (1), 47-57. in Russian.

Tsai J.F., Chen S.C., Lin Z.Y., Dai C.Y., Huang J.F., Yu M.L., Chuang W.L. (2017). Independent and additive interaction between polymorphisms of tumor necrosis factor α− 308 and lymphotoxin α+ 252 on risk of hepatocellular carcinoma related to hepatitis B. The Kaohsiung journal of medical sciences, 33 (9), 453-457.

Li J., Wang Y., Chang X., Han Z. (2020). The effect of LTA gene polymorphisms on cancer risk: an updated systematic review and meta-analysis. Bioscience reports, 40 (5), BSR20192320.

Takei K., Ikeda S., Arai T., Tanaka N., Muramatsu M., Sawabe M. (2008). Lymphotoxin-alpha polymorphisms and presence of cancer in 1,536 consecutive autopsy cases. BMC cancer, 8 (1), 1-6.

Campbell M.C., Ashong B., Teng S., Harvey J., Cross C.N. (2019). Multiple selective sweeps of ancient polymorphisms in and around LTα located in the MHC class III region on chromosome 6. BMC evolutionary biology, 19 (1), 1-20.

Gong L.L., Han F.F., Lv Y.L., Liu H., Wan Z.R., Zhang W., Shi M.B., Pei L.X., Liu L.H. (2017). TNF-α and LT-α Polymorphisms and the Risk of Leukemia: A Meta-analysis. Tumori Journal, 103 (1), 53-59.

Um J.Y., An N.H., Kim H.M. (2003). TNF-α and TNF-β gene polymorphisms in cerebral infarction. Journal of Molecular Neuroscience, 21 (2), 167-171.

D'Souza W.N., Chang C.F., Fischer A.M., Li M., & Hedrick S.M. (2008). The Erk2 MAPK regulates CD8 T cell proliferation and survival. The Journal of Immunology, 181 (11), 7617-7629. https://doi.org/10.4049/jimmunol.181.11.7617

Verma V., Jafarzadeh N., Boi S., Kundu S., Jiang Z., Fan Y., Lopez J., Nandre R., Zeng P., Alolaqi F., Ahmad S., Gaur P., Barry S.T., Valge-Archer V.E., Smith P.D., Banchereau J., Mkrtichyan M., Youngblood B., Rodriguez P.C., Gupta S., Khleif S.N. (2021). MEK inhibition reprograms CD8+ T lymphocytes into memory stem cells with potent antitumor effects. Nature Immunology, 22 (1), 53-66. https://doi.org/10.1038/s41590-020-00818-9

Damasio M.P., Marchingo J.M., Spinelli L., Hukelmann J.L., Cantrell D.A., Howden A.J. (2021). Extracellular signal-regulated kinase (ERK) pathway control of CD8+ T cell differentiation. Biochemical Journal, 478 (1), 79-98.

Voon D.C., Subrata L.S., Karimi M., Ulgiati D., Abraham L.J. (2004). TNF and phorbol esters induce lymphotoxin-β expression through distinct pathways involving Ets and NF-κB family members. The Journal of Immunology, 172 (7), 4332-4341.

Piao W., Xiong Y., Li L., Saxena V., Smith K.D., Hippen K.L., Paluskievicz C., Willsonshirkey M., Blazar B.R., Abdi R., Bromberg J.S. (2020). Regulatory T cells condition lymphatic endothelia for enhanced transendothelial migration. Cell reports, 30 (4), 1052-1062.

Husson H., Lugli S.M., Ghia P., Cardoso A., Roth A., Brohmi K., Carideo E.G., Choi Y.S., Browning, J., Freedman A.S. (2000). Functional effects of TNF and lymphotoxin α1β2 on FDC-like cells. Cellular immunology, 203 (2), 134-143.

Guo Z., Qiu C., Mecca C., Zhang Y., Bian J., Wang Y., Wu X., Wang T., Su W., Li X., Zhang W., Chen B., Xiang H. (2021). Elevated lymphotoxin-α (TNFβ) is associated with intervertebral disc degeneration. BMC musculoskeletal disorders, 22 (1), 1-10.

Шмидт Е.А. и др. Связь вариабельного сайта rs1041981 гена лимфотоксина-α с развитием неблагоприятных исходов у пациентов с острым коронарным синдромом без подъема сегмента ST в отдаленном периоде //Медицинская иммунология. – 2018. – Т. 20. – №. 1.

Shmidt E.A., Berns S.A., Zhidkova I.I., Makeeva O.A., Goncharova I.A., Nagirnyak O.A., Klimenkova A.V., Litvinova M. N., Barbarash, O.L. (2018). Association of a lymphotoxin-α variable site rs1041981 with development of long-term unfavorable outcomes in patients with acute coronary syndrome without ST-segment elevation. Meditsinskaya immunologiya (Russia), 20 (1), 73-84. in Russian.

Constanze B., Popper B., Aggarwal B.B., Shakibaei M. (2020). Evidence that TNF-β suppresses osteoblast differentiation of mesenchymal stem cells and resveratrol reverses it through modulation of NF-κB, Sirt1 and Runx2. Cell and tissue research, 381 (1), 83-98.

Buhrmann C., Busch F., Shayan P., Shakibaei M. (2014). Sirtuin-1 (SIRT1) is required for promoting chondrogenic differentiation of mesenchymal stem cells. Journal of Biological Chemistry, 289 (32), 22048-22062. https://doi.org/10.1074/jbc.M114.568790

Calmon-Hamaty, F., Combe, B., Hahne, M., Morel, J. (2011). Lymphotoxin α revisited: general features and implications in rheumatoid arthritis. Arthritis research & therapy, 13 (4), 1-5. https://doi.org/10.1186/ar3376

Marston B., Palanichamy A., Anolik J.H. (2010). B cells in the pathogenesis and treatment of rheumatoid arthritis. Current opinion in rheumatology, 22 (3), 307.

Pala O., Diaz A., Blomberg B.B., Frasca D. (2018). B lymphocytes in rheumatoid arthritis and the effects of anti–TNF-α agents on B lymphocytes: a review of the literature. Clinical therapeutics, 40 (6), 1034-1045.

Buhrmann C., Shayan P., Aggarwal B.B., Shakibaei M. (2013). Evidence that TNF-β (lymphotoxin α) can activate the inflammatory environment in human chondrocytes. Arthritis research & therapy, 15 (6), 1-14. https://doi.org/10.1186/ar4393

Насонов Е.Л. (2001). Фактор некроза опухоли-α–новая мишень для противовоспалительной терапии ревматоидного артрита. Клиническая фармакология и терапия, 1, 64-70.

Nasonov E.L. (2001). Tumor necrosis factor-α -a new target for anti-inflammatory treatment of rheumatoid arthritis. Sovremennaya revmatologiya, 1, 64-70. in Russian.

Каратеев Д.Е. Насколько реально длительное сохранение лечебного эффекта ингибиторов фактора некроза опухоли α? Фокус на иммуногенность //Современная ревматология. – 2014. – №. 2. – С. 24-29.

Karateev D.E. (2014). How real is the long-lasting effect of tumor necrosis factor α inhibitors? Focus on immunogenicity. Sovremennaya revmatologiya, 8 (2), 35-40. in Russian.

Каратеев Д.Е. Этанерцепт (обзор международных исследований). Научно-практическая ревматология. 2009; 47 (5): 52-57. https://doi.org/10.14412/1995-4484-2009-589

Karateev D.E. (2009). Etanercept (review of international studies). Nauchno-prakticheskaya revmatologiya, 47 (5), 52-57. in Russian. https://doi.org/10.14412/1995-4484-2009-589

Werner F., Wagner C., Simon M., Glatz K., Mertz K.D., Läubli H., Richtig E., Griss J., Wagner S.N. (2021). Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma. Diagnostics, 11 (7), 1238.

Yang D., Ud Din N., Browning D.D., Abrams S.I., & Liu K. (2007). Targeting lymphotoxin β receptor with tumor-specific T lymphocytes for tumor regression. Clinical cancer research, 13 (17), 5202-5210.

Dimitrakopoulos F.I.D., Kottorou A.E., Antonacopoulou A.G., Panagopoulos N., Scopa C., Kalofonou M., Dougenis D., Koutras A., Makatsortis T., Tzelepi V., Kalofonos H.P. (2019). Expression of immune system-related membrane receptors CD40, RANK, BAFFR and LTβR is associated with clinical outcome of operated non-small-cell lung cancer patients. Journal of clinical medicine, 8 (5), 741.

Conlon T.M., John-Schuster G., Heide D., Pfister D., Lehmann M., Hu Y., Ertüz Z., Lopez M.A., Ansari M., Strunz M., Mayr C., Ciminieri C., Costa R., Kohlhepp M.S., Guillot A., Günes G., Jeridi A., Funk M.C., Beroshvili G., Prokosch S., Hetzer J., Verleden S.E., Alsafadi H., Lindner M., Burgstaller G., Becker L., Irmler M., Dudek M., Janzen J., Goffin E., Gosens R., Knolle P., Pirotte B., Stoeger T., Beckers J., Wagner D., Singh I., Theis F.J., Hrabé de Angelis M., O’Connor T.O., Tacke F., Boutros M., Dejardin E., Eickelberg O., Schiller H.B., Königshoff M., Heikenwalder M., Yildirim A.Ö. (2020). Inhibition of LTβR signalling activates WNT-induced regeneration in lung. Nature, 588 (7836), 151-156.

Das R., Coupar J., Clavijo P.E., Saleh A., Cheng T.F., Yang X., Chen J., VanWaes C., Chen Z. (2019). Lymphotoxin‐β receptor‐NIK signaling induces alternative RELB/NF‐κB2 activation to promote metastatic gene expression and cell migration in head and neck cancer. Molecular carcinogenesis, 58 (3), 411-425.

Tang H., Zhu M., Qiao J., Fu Y.X. (2017). Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy. Cellular & molecular immunology, 14(10), 809-818.

Buhrmann C., Kunnumakkara A.B., Popper B., Majeed M., Aggarwal B.B., Shakibaei M. (2020). Calebin A potentiates the effect of 5-FU and TNF-β (lymphotoxin α) against human colorectal cancer cells: potential role of NF-κB. International journal of molecular sciences, 21 (7), 2393.

Giles D.A., Zahner S., Krause P., Van Der Gracht E., Riffelmacher T., Morris V., Tumanov A., Kronenberg M. (2018). The tumor necrosis factor superfamily members TNFSF14 (LIGHT), lymphotoxin β and lymphotoxin β receptor interact to regulate intestinal inflammation. Frontiers in immunology, 9, 2585. doi: 10.3389/fimmu.2018.02585.

Buhrmann C., Yazdi M., Popper B., Shayan P., Goel A., Aggarwal B.B., Shakibaei M. (2018). Resveratrol chemosensitizes TNF-β-induced survival of 5-FU-treated colorectal cancer cells. Nutrients, 10 (7), 888. doi: 10.3390/nu10070888.

Buhrmann C., Popper B., Kunnumakkara A.B., Aggarwal B.B., Shakibaei M. (2019). Evidence that Calebin A, a component of curcuma longa suppresses NF-κB mediated proliferation, invasion and metastasis of human colorectal cancer induced by TNF-β (Lymphotoxin). Nutrients, 11 (12), 2904. doi: 10.3390/nu11122904.

Wang F.H., Wang Y., Sun G.P., Chen J.H., Lin Y.C., Liu W., Zheng R.S., Chen J., Zhang H.L., Lan H.T., Qi J., Liu Y.Q., Deng Y.M., Zhao H., Xiong J.P., Xu Q., Jiang W.Q., Li Y.H. (2017). Efficacy and safety of recombinant human lymphotoxin‐α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open‐label, controlled, phase 2b trial. Cancer, 123 (20), 3986-3994.

Yang J.G., Wang W.M., Xia H.F., Yu Z.L., Li H.M., Ren J.G., Chen G., Wang B.K., Jia J., Zhang W., Zhao Y.F. (2019). Lymphotoxin‐α promotes tumor angiogenesis in HNSCC by modulating glycolysis in a PFKFB3‐dependent manner. International journal of cancer, 145 (5), 1358-1370.

von Hoff L., Kärgel E., Franke V., McShane E., Schulz-Beiss K.W., Patone G., Schleussner N., Kolesnichenko M., Hübner N., Daumke O., Selbach M., Akalin A., Mathas S., Scheidereit C. (2019). Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. Blood, The Journal of the American Society of Hematology, 133 (13), 1489-1494. doi: 10.1182/blood-2018-08-871293.

The authors declare that there are no conflicts of interest present.